1. Home
  2. LDP vs MLYS Comparison

LDP vs MLYS Comparison

Compare LDP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Limited Duration Preferred and Income Fund Inc.

LDP

Cohen & Steers Limited Duration Preferred and Income Fund Inc.

HOLD

Current Price

$21.38

Market Cap

628.4M

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$33.13

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDP
MLYS
Founded
2012
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
628.4M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
LDP
MLYS
Price
$21.38
$33.13
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$47.33
AVG Volume (30 Days)
102.5K
1.5M
Earning Date
01-01-0001
02-11-2026
Dividend Yield
7.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.16
$8.24
52 Week High
$20.30
$47.65

Technical Indicators

Market Signals
Indicator
LDP
MLYS
Relative Strength Index (RSI) 54.30 29.64
Support Level $21.28 $34.21
Resistance Level $21.45 $37.70
Average True Range (ATR) 0.14 1.56
MACD 0.03 -0.13
Stochastic Oscillator 70.00 14.42

Price Performance

Historical Comparison
LDP
MLYS

About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.

Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: